Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S13-20.

Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia.

Author information

1
Weill Cornell Medical College, New York, New York 10021, USA. run9001@med.cornell.edu

Abstract

Venous thromboembolism (VTE), osteonecrosis of the jaw, renal failure, and anemia are all common complications of multiple myeloma therapy. Many of these adverse events have been documented only in the past 5 to 10 years, in conjunction with the introduction of a series of the newer therapies thalidomide, bortezomib, and lenalidomide. This article discusses these complications in detail and provides strategies for health care providers to best prevent, identify, and manage them. Preventive measures, such as VTE prophylaxis and appropriate dental hygiene, as well as patient education, dose adjustments, limited duration of drug treatment, and consideration of therapies that are associated with less burdensome adverse-event profiles, can contribute to substantially improved outcomes and quality of life.

PMID:
20141670
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center